DCPH Quantitative Stock Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2024
0mins
Source: NASDAQ.COM
- Validea's Guru Fundamental Report: Validea's analysis rates DECIPHERA PHARMACEUTICALS INC (DCPH) highest using the Small-Cap Growth Investor model based on Motley Fool's strategy.
- DECIPHERA PHARMACEUTICALS INC (DCPH): It is a mid-cap growth stock in the Biotechnology & Drugs industry with a 65% rating based on fundamentals and valuation.
- Motley Fool: Provides frank and irreverent commentary on investing, the stock market, and personal finance. Founded by David and Tom Gardner.
- Additional Research Links: Include top healthcare stocks, Dividend Aristocrats 2024, wide moat stocks, recession-proof stocks, high insider ownership stocks, and factor-based stock portfolios.
- About Validea: An investment research service that follows strategies of investment legends like Warren Buffett, Benjamin Graham, Peter Lynch, and Martin Zweig.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
